http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Rula (검색결과 6 건)
- 무료
- 기관 내 무료
- 유료
-
Mohammad Ma’koseh,Rula Amarin,Faris Tamimi,Baha’ Sharaf,Alaa Abufara,Omar Shahin,Mohammed K. M. Manassra,Khalid Halahleh 대한혈액학회 2021 Blood Research Vol.56 No.4
Background The treatment of adult Burkitt lymphoma with pediatric-based chemotherapy protocols usually results in high cure rates, although with significant toxicity. We report our experience with the Cancer and Leukemia Group B1002 (CALGB 1002) protocol. Methods The files of adult patients diagnosed with Burkitt lymphoma and treated with the CALGB 1002 protocol at King Hussein Cancer Center between 2008 and 2017 were reviewed. Baseline demographics, clinical laboratory features, treatment details, and responses were collected. The correlations between clinical and laboratory variables with event-free survival (EFS) and overall survival (OS) were determined by univariate and multivariate analyses using backward stepwise Cox regression models. EFS and OS were plotted using Kaplan‒Meier curves. Results This study included 19 patients with a median age of 33 years (range, 19‒65). Eleven (58%) and two (10.5%) patients had advanced-stage and central nervous system disease, respectively. Among 106 administered cycles, the median interval between cycles was 23 days (range, 19‒84 days). Sixteen patients (84%) achieved a complete response. After a median follow-up of 40.8 months, the 3-year EFS and OS rates were 78.95%. Patients with a low-risk International Prognostic Index (IPI) had better survival than those with intermediate-or high-risk IPI. Grade III‒IV hematological toxicities occurred in 88% of patients, while 73% had grade III‒IV mucositis. Conclusion In adult Burkitt lymphoma, the CALGB 1002 protocol provides high cure rates and can be administered promptly, but is associated with significant toxicity. Risk-adapted approaches and other, less toxic, chemotherapeutic regimens should be considered.
-
Wu Vickie,Zhao Victoria,Issa Rula,Wilkes Meredith,Wallach Elizabeth,Rapaport Robert,Romero Christopher,Yau Mabel 대한소아내분비학회 2021 Annals of Pediatirc Endocrinology & Metabolism Vol.26 No.3
Purpose: This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche.Methods: We retrospectively reviewed medical records of 39 females with CPP who reached menarche after GnRHa treatment (leuprolide or histrelin). CPP diagnostic criteria were breast development at <8 years old, measurable pubertal luteinizing hormone and/or estradiol concentrations, and bone age advancement. Indications to treat were advanced bone age and psychosocial concerns. Descriptive summaries were reported as frequency and proportion for categorical variables and mean and standard deviation for continuous measures. Linear regression models were developed to evaluate the associations of clinical factors with the time interval to menarche.Results: Mean age was 9.4±1.6 years at treatment onset, and treatment duration was 2.2±1.4 years. Menarche occurred at 12.6±1.1 years, which was 1.04±0.5 years after treatment discontinuation. This was negatively associated with Tanner stage of breast development and bone age at treatment onset and change in bone age during treatment. No association was seen between time interval to menarche and treatment duration, medication, or body mass index.Conclusion: We found the average time interval to menarche after GnRHa treatment in our population of female patients with CPP to be 1.04±0.5 years; this is in agreement with other reports. Tanner stage of breast development, bone age at treatment onset, and change in bone age were negatively associated with time interval to menarche. These data provide clinical correlates that assist providers during anticipatory guidance of patients with CPP after GnRHa treatment.
-
-
Effect of Palestinian Honey on Spermatogenesis in Rats
Abdul-Salam Abdul-Ghani,Nabil Dabdoub,Rateb Muhammad,Rula Abdul-Ghani,Munir Qazzaz 한국식품영양과학회 2008 Journal of medicinal food Vol.11 No.4
Treatment of male albino rats with 5% honey for 20 days had no significant effect on total body weight or on the relative weight of other organs like the testis, seminal vesicles, spleen, kidneys, liver, heart, or brain. The only significant change was a 17% increase in the relative weight of the epididymis (P ≤ .01). The relative weight of all the other organs was similar to those in control animals treated for the same period with drinking water. Treatment of rats for the same period with the same concentration of 5% sucrose produced no significant changes in absolute or relative weight of tested organs compared to control animals. The same treatment with Palestinian honey increased significantly the epididymal sperm count by 37% (P ≤ .05). The activity of testicular marker enzymes for spermatogenesis such as sorbitol dehydrogenase (SDH) was increased by 31% (P ≤ .05), and lactate dehydrogenase (LDH) was reduced by 48% (P ≤ .05), which indicates that treatment with honey induces spermatogenesis. Similar treatment with sucrose had no significant effect on any of the key enzymes or epididymal sperm count. In conclusion, our results show that ingestion of honey induces spermatogenesis in rats by increasing epididymal sperm count, increasing selectively the relative weight of the epididymis, and increasing SDH activity and reducing LDH activity.
-
-
Risk factors for orthodontic fixed retention failure: A retrospective controlled study
Verschueren Kaat,Rajbhoj Amit Arvind,Begnoni Giacomo,Willems Guy,Verdonck Anna,Cadenas de Llano-Pérula Maria 대한치과교정학회 2023 대한치과교정학회지 Vol.53 No.6
Objective: To investigate the potential correlation between fixed orthodontic retention failure and several patient- and treatment-related factors. Methods: Patients finishing treatment with fixed appliances between 2016 and 2017 were retrospectively included in this study. Those not showing fixed retention failure were considered as control group. Patients with fixed retention failure were considered as the experimental group. Additionally, patients with failure of fixed retainers in the period of June 2019 to March 2021 were prospectively identified and included in the experimental group. The location of the first retention failure, sex, pretreatment dental occlusion, facial characteristics, posttreatment dental occlusion, treatment approach and presence of oral habits were compared between groups before and after treatment separately by using a Fisher exact test and a Mann–Whitney U test. Results: 206 patients with fixed retention failure were included, 169 in the mandibular and 74 in the maxillary jaws. Significant correlations were observed between retention failure in the mandibular jaws and mandibular arch length discrepancy (P = 0.010), post-treatment growth pattern (P = 0.041), nail biting (P < 0.001) and abnormal tongue function (P = 0.002). Retention failure in the maxillary jaws was more frequent in patients with IPR in the mandibular jaws (P = 0.005) and abnormal tongue function (P = 0.021). Conclusions: This study suggests a correlation between fixed retention failure and parafunctional habits, such as nail biting and abnormal tongue function. Prospective studies with larger study populations could further confirm these results.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
